Hello Cook County Department of Public Health Partner,

Yesterday, CDC issued Emergency Use Instructions (EUI) and updated its clinical considerations to allow the COVID-19 vaccine by Pfizer-BioNTech to be given as an additional primary dose or booster dose to certain people who completed a vaccine primary series with certain COVID-19 vaccines that are not authorized or approved by the U.S. Food and Drug Administration. This ensures that eligible people who were vaccinated outside of the U.S. with these vaccines, or who received certain non-FDA authorized or approved COVID-19 vaccines through participation in some clinical trials, can get an additional primary dose or booster dose of Pfizer-BioNTech COVID-19 vaccine.

WHO has listed the following COVID-19 vaccines for emergency use:
- Pfizer-BioNTech COVID-19 Vaccines (e.g., BNT162b2, COMIRNATY, Tozinameran)
- AstraZeneca-Oxford COVID-19 Vaccines (e.g., [ChAdOx1-S (recombinant)], AZD1222, Covishield, Vaxzevria)
- Janssen (Johnson & Johnson) COVID-19 Vaccine (e.g., Ad26.COV2.S)
- Moderna COVID-19 Vaccine (e.g., mRNA 1273, Takeda, Spikevax)
- Sinopharm-BIBP COVID-19 Vaccine
- Sinovac-CoronaVac COVID-19 Vaccine
- Bharat Biotech International COVID-19 Vaccines (e.g., BBV152, COVAXIN)

The new guidance mirrors CDC’s recommendations about who is eligible to receive boosters and additional primary doses, allowing an additional primary dose of the COVID-19 vaccine by Pfizer-BioNTech in certain immunocompromised persons aged 12 years and older, and/or a single booster dose of Pfizer-BioNTech COVID-19 vaccine in certain adults 18 years and older who completed their primary vaccination with a non-FDA authorized or approved COVID-19 vaccines. Below is a list of resources and upcoming informational activities related to the recommendation:

- EUI Healthcare Provider Fact Sheet and EUI Recipient/Caregiver Fact Sheet
- Updated Clinical Considerations

- Updated guidance in section on People who received COVID-19 vaccine outside the United States
- Updated guidance in section on People who received COVID-19 as part of a clinical trial
- Tentative ACIP Meeting Friday 11/19 11a-2p CST to consider expanding booster eligibility